Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Israeli Study Finds Cannabis Oil Improves Autism-Related Symptoms in Teens
Error: Contact form not found.
by JNS.org
An employee sorts freshly harvested cannabis buds at a medical marijuana plantation in northern Israel on March 21, 2017. Photo: REUTERS/Nir Elias/File Photo.
JNS.org – A new Israeli study shows that more than 80 percent of children with autism-related symptoms who took cannabis oil enjoyed moderate to significant improvement in their condition.
A six-month study at Ben-Gurion University in the Negev and Soroka Medical Center in Beersheva found that 30 percent of patients reported significant improvement and 53.7 percent of patients reported moderate improvement regarding symptoms such as seizures, tics, depression, restlessness and rage attacks after taking the cannabidiol-rich treatment with an addition of 1.5 percent THC on a regular basis.
The study, funded by medical marijuana firm Tikun Olam and titled “Real Life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy,” tested 188 teenagers on the autism spectrum between 2015 and 2017.
After treatment concluded, 66.8 percent of patients said they had a good quality of life, compared to the 31.3 percent who identified their lives as such prior to the report, and 63.5 percent said they were in positive moods, as compared to 42 percent prior to the beginning of the study.
The authors lauded the success of the study and said they want to move on to double-blind placebo-controlled trials.
